» Articles » PMID: 38455419

Arsenic Trioxide Suppresses Lung Adenocarcinoma Stem Cell Stemness by Inhibiting M6A Modification to Promote Ferroptosis

Overview
Journal Am J Cancer Res
Specialty Oncology
Date 2024 Mar 8
PMID 38455419
Authors
Affiliations
Soon will be listed here.
Abstract

Arsenic trioxide (ATO) is well known for its inhibitory effects on cancer progression, including lung adenocarcinoma (LUAD), but the molecular mechanism remains elusive. This study aimed to investigate the roles of ATO in regulating LUAD stem cells (LASCs) and the underlying mechanisms. To induce LASCs, cells cultured in an F12 medium, containing B27, epidermal growth factor, and basic fibroblast growth factor, induced LASCs. LASCs stemness was assessed through tumor sphere formation assay, and percentages of CD133+ cells were detected by flow cytometry. The Cell Counting Kit-8 method was used to assess LASCs viability, while reactive oxygen species (ROS) and iron ion levels were quantitated by fluorescence microscopy and spectrophotometry, respectively, and total m6A levels were measured by dot blot. Additionally, LASCs mitochondrial alterations were analyzed via transmission electron microscopy. Finally, the tumorigenicity of LASCs was assessed using a cancer cell line-based xenograft model. Tumor sphere formation and CD133 expression were used to validate the successful induction of LASCs from A549 and NCI-H1975 cells. ATO significantly inhibited proliferation, reduced ZC3H13 expression and total m6A modification levels, and increased ROS and iron ion content, but repressed sphere formation and CD133 expression in LASCs. ZC3H13 overexpression or ferrostatin-1 treatment abrogated LASCs stemness inhibition caused by ATO treatment, and interference with ZC3H13 inhibited LASCs stemness. Furthermore, the promotion of LASCs ferroptosis by ATO was effectively mitigated by ZC3H13 overexpression, while interference with ZC3H13 further promoted ferroptosis. Moreover, si-ZC3H13 promoted ferroptosis and impaired stemness in LASCs, which ferrostatin-1 abrogated. Finally, ZC3H13 overexpression alleviated the inhibitory effects of ATO on LASCs tumorigenicity. Taken together, ATO treatment substantially impaired the stemness of LUAD stem cells by promoting the ferroptosis program, which was mediated by its ZC3H13 gene expression inhibition to suppress m6A medication.

Citing Articles

Molecular mechanism of ZC3H13 -mediated ferroptosis in doxorubicin resistance of triple negative breast cancer.

Huang L, Han L, Liang S, Han G Cell Biol Toxicol. 2025; 41(1):52.

PMID: 40000487 PMC: 11861033. DOI: 10.1007/s10565-024-09980-4.

References
1.
Wang X, Chen Y, Wang X, Tian H, Wang Y, Jin J . Stem Cell Factor SOX2 Confers Ferroptosis Resistance in Lung Cancer via Upregulation of SLC7A11. Cancer Res. 2021; 81(20):5217-5229. PMC: 8530936. DOI: 10.1158/0008-5472.CAN-21-0567. View

2.
Zhang L, Shen L, Wu D . Clinical significance of cancer stem cell markers in lung carcinoma. Acta Biochim Pol. 2021; 68(2):187-191. DOI: 10.18388/abp.2020_5498. View

3.
Wang H, Zhang B, Zhou J, Wang D, Xu Y, Zeng Q . Arsenic trioxide inhibits liver cancer stem cells and metastasis by targeting SRF/MCM7 complex. Cell Death Dis. 2019; 10(6):453. PMC: 6560089. DOI: 10.1038/s41419-019-1676-0. View

4.
Seibt T, Proneth B, Conrad M . Role of GPX4 in ferroptosis and its pharmacological implication. Free Radic Biol Med. 2018; 133:144-152. DOI: 10.1016/j.freeradbiomed.2018.09.014. View

5.
Wang Y, Zhao G, Condello S, Huang H, Cardenas H, Tanner E . Frizzled-7 Identifies Platinum-Tolerant Ovarian Cancer Cells Susceptible to Ferroptosis. Cancer Res. 2020; 81(2):384-399. PMC: 7855035. DOI: 10.1158/0008-5472.CAN-20-1488. View